NCT05440383View on ClinicalTrials.gov

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia

PHASE3CompletedINTERVENTIONAL
Enrollment

287

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

August 21, 2024

Study Completion Date

August 21, 2024

Conditions
Uterine Fibroids (MeSH Heading: Leiomyoma)
Interventions
DRUG

KLH-2109

Oral administration

DRUG

Leuprorelin

Subcutaneous administration

Trial Locations (1)

Unknown

Clinical Resarch Site, Multiple Locations

Sponsors
All Listed Sponsors
lead

Kissei Pharmaceutical Co., Ltd.

INDUSTRY